Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533194 · ClinicalTrials.gov registry record · Phase 1
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Refractory Plasma Cell Myeloma and Light Chain Deposition Disease, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01533194 is a Phase 1 study of Refractory Plasma Cell Myeloma and Light Chain Deposition Disease that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants, below the 46-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01533194, a Phase 1 study of Refractory Plasma Cell Myeloma and Light Chain Deposition Disease, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot phase I trial studies the side effects and the best dose of giving viral therapy to patients with relapsed or refractory multiple myeloma. Viral therapy, such as wild-type reovirus, may be able to kill cancer cells without damaging normal cells.
Conditions Studied
Interventions
- OTHER Diagnostic Laboratory Biomarker Analysis
- BIOLOGICAL Wild-type Reovirus
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533194
The ClinicalTrials.gov registry entry for NCT01533194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 46-participant average among 25 other Refractory Plasma Cell Myeloma trials with a reported enrollment target (74% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Diagnostic Laboratory Biomarker Analysis is the first listed.
NCT01533194 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01533194 about?
NCT01533194 is a clinical study titled "Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma". This pilot phase I trial studies the side effects and the best dose of giving viral therapy to patients with relapsed or refractory multiple myeloma. Viral therapy, such as wild-type reovirus, may be able to kill cancer cells without damaging normal cells.
What is the current status of trial NCT01533194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-04. Estimated completion is 2015-02.
What conditions does trial NCT01533194 study?
This clinical trial studies the following conditions: Refractory Plasma Cell Myeloma, Light Chain Deposition Disease.
What interventions are being tested in trial NCT01533194?
The interventions under investigation include: Diagnostic Laboratory Biomarker Analysis (OTHER), Wild-type Reovirus (BIOLOGICAL).
Who is sponsoring clinical trial NCT01533194?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01533194 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
RECRUITING · Phase 1
-
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
ACTIVE NOT RECRUITING · Phase 1
-
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.